---
title: "SKY-0515 in Huntington's disease: References"
description: "Reference list for the formulary evidence report on SKY-0515 in Huntington's disease. 211 cited documents."
canonical: "https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/references"
published: "2026-09-16T18:00:43-04:00"
modified: "2026-10-22T19:07:03-04:00"
---

# SKY-0515 in Huntington's disease: References

<a id="references"></a>

## 5 References

1. [Achenbach and Saft (2021)](https://pubmed.ncbi.nlm.nih.gov/34049236/)
2. [Ajitkumar et al. (2025)](https://www.ncbi.nlm.nih.gov/books/NBK559166/)
3. [AMCP (2024)](https://www.amcp.org/sites/default/files/2024-04/AMCP-Format-5.0-JMCP-web_0.pdf)
4. [American Academy of Neurology (2022)](https://www.aan.com/Guidelines/home/GuidelineDetail/558)
5. [American Academy of Neurology movement disorders quality measures](https://www.aan.com/practice/movement-disorders-quality-measures)
6. [Anderson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6294590/)
7. [Andriessen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998698/)
8. [ANZCTR ACTRN12623001161617](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386527)
9. [ANZCTR ACTRN12624000602527](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387624)
10. [Armstrong and Miyasaki (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413759/)
11. [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)
12. [Baig et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5027682/)
13. [Bardakjian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31381522/)
14. [Barer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10366633/)
15. [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)
16. [Bayen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36055643/)
17. [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)
18. [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/)
19. [Bombard et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694258/)
20. [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)
21. [Burgunder et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3166256/)
22. [Byrne et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5507767/)
23. [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)
24. [Carlozzi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108175/)
25. [Carlozzi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28556412/)
26. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38142687/)
27. [Christensen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35618525/)
28. [Claassen et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5331691/)
29. [Claassen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8216765/)
30. [Claassen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8990962/)
31. [ClinicalTrials.gov NCT03628235](https://clinicaltrials.gov/study/NCT03628235)
32. [ClinicalTrials.gov NCT06873334](https://clinicaltrials.gov/study/NCT06873334)
33. [ClinicalTrials.gov NCT07378644](https://clinicaltrials.gov/study/NCT07378644)
34. [ClinicalTrials.gov NCT07537075](https://clinicaltrials.gov/study/NCT07537075)
35. [Coppen and Roos (2017)](https://pubmed.ncbi.nlm.nih.gov/27988871/)
36. [da Silva van der Laan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39150831/)
37. [DailyMed AUSTEDO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0)
38. [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)
39. [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)
40. [Divino et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23789925/)
41. [Dorey et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5065694/)
42. [Drug Discovery and Development (2023)](https://www.drugdiscoverytrends.com/reata-sets-370000-annual-cost-for-new-nerve-disorder-drug/)
43. [Ekkel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37269816/)
44. [El-Sourady et al. (2022)](https://journals.sagepub.com/doi/full/10.1089/jpm.2021.0308)
45. [Erwin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3593716/)
46. [Evans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786631/)
47. [Exuzides et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34730477/)
48. [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/)
49. [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/)
50. [Exuzides et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/35608039/)
51. [Farag et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)
52. [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)
53. [Fisher and Hayden (2014)](https://pubmed.ncbi.nlm.nih.gov/24151181/)
54. [Fox and Harding (2026)](https://en.hdbuzz.net/encouraging-news-from-skyhawk-as-sky-0515-phase-1-2-data-continues-to-hold-promise/)
55. [Frank et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39825184/)
56. [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284)
57. [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)
58. [Furr Stimming et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37210099/)
59. [Furr Stimming et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089624/)
60. [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)
61. [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)
62. [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524551/)
63. [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6700281/)
64. [Gokhale and Villa Zapata (2025)](https://pubmed.ncbi.nlm.nih.gov/39973389/)
65. [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)
66. [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)
67. [Hall et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11515112/)
68. [Handsaker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11822645/)
69. [Harding (2025)](https://en.hdbuzz.net/sky-0515-lowers-huntingtin-in-people-with-huntingtons-disease-in-trial-update/)
70. [Harding (2026a)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)
71. [Harding (2026b)](https://en.hdbuzz.net/skyhawk-reports-encouraging-12-month-results-for-oral-huntingtons-disease-drug-sky-0515/)
72. [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36698999/)
73. [Hawkins et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3548262/)
74. [Hawton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856291/)
75. [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)
76. [Hensman Moss et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28642124/)
77. [Hergert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33723593/)
78. [Hernandez (2024)](https://en.hdbuzz.net/373/)
79. [Hernandez (2026a)](https://en.hdbuzz.net/australia-opens-the-door-for-sky-0515-skyhawk-seeks-provisional-approval-for-its-oral-hd-drug/)
80. [Hernandez (2026b)](https://en.hdbuzz.net/skyhawk-shares-a-closer-look-at-sky-0515-data-plus-a-peek-at-expanding-us-trial-access/)
81. [Herzog-Krzywoszanska and Krzywoszanski (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474183/)
82. [Ho et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19097181/)
83. [Hubers et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22119091/)
84. [Hubers et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23876196/)
85. [Huntington Study Group (2006)](https://pubmed.ncbi.nlm.nih.gov/16476934/)
86. [Huntington Study Group (2016)](https://pubmed.ncbi.nlm.nih.gov/27380342/)
87. [Huntington's Disease News (2026)](https://huntingtonsdiseasenews.com/news/hdsa-2026-oral-therapies-take-center-stage-huntingtons-trials/)
88. [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)
89. [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)
90. [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)
91. [Huntington's Disease Society of America genetic testing and your rights](https://hdsa.org/find-help/healthcare-and-future-planning/genetic-testing-and-your-rights/)
92. [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-gene-therapy-for-huntingtons-disease/)
93. [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)
94. [ICER reference case (2025)](https://icer.org/wp-content/uploads/2024/02/ICER_Reference-Case_For-Publication_070126.pdf)
95. [Inbar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13379509/)
96. [Johnson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916295/)
97. [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)
98. [Kachian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30875675/)
99. [Kay et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955276/)
100. [Keum et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4746370/)
101. [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39373538/)
102. [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)
103. [Ko et al. (2020)](https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/)
104. [Langbehn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15025718/)
105. [Langbehn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6692683/)
106. [Lee et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9118113/)
107. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846961/)
108. [MacLeod et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22642570/)
109. [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome)
110. [Martinez-Horta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26898966/)
111. [Massey et al. (2021)](https://www.mdsabstracts.org/abstract/cost-of-predictive-genetic-testing-for-huntingtons-disease-at-centers-of-excellence-in-the-us/)
112. [McColgan and Tabrizi (2018)](https://pubmed.ncbi.nlm.nih.gov/28817209/)
113. [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)
114. [McLean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11015039/)
115. [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)
116. [MedlinePlus (2020)](https://medlineplus.gov/genetics/condition/huntington-disease/)
117. [Mestre et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19588393/)
118. [Mestre et al. (2009b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390161/)
119. [Miller et al. (2026a)](https://cdn.prod.website-files.com/6a79db26db17270ba01110b3/6aa7f7bdccaec6d796485c8d_Skyhawk_CHDI_2026_poster_FINAL.pdf)
120. [Miller et al. (2026b)](https://cdn.prod.website-files.com/6a79db26db17270ba01110b3/6aa33cccb8099e3cc7aac64e_Skyhawk_EAN_Investigation_of_SKY-0515_Patients_Huntingtons_Disease_26June26.pdf)
121. [Mills et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39101272/)
122. [Morrison et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20880124/)
123. [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/)
124. [NINDS (2026)](https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease)
125. [Ogilvie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12021023/)
126. [Ogilvie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316193/)
127. [Ohlmeier et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6905058/)
128. [Oosterloo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307030/)
129. [Oster et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2574833/)
130. [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285853/)
131. [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)
132. [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)
133. [Paulsen et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737562/)
134. [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)
135. [Pollard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11576117/)
136. [Poprelka et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40938830/)
137. [Pringsheim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22692795/)
138. [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)
139. [Quinn et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7080285/)
140. [Rawlins et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26824438/)
141. [Reilmann (2013)](https://pubmed.ncbi.nlm.nih.gov/23674480/)
142. [Reilmann et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25164527/)
143. [Reilmann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618238/)
144. [Research and Markets (2026)](https://www.globenewswire.com/news-release/2026/09/08/3357902/28124/en/huntington-s-disease-market-insight-epidemiology-and-market-forecast-2036-now-available-see-which-pipeline-candidates-are-racing-to-become-the-first-disease-modifying-therapy.html)
145. [Roche (2021)](https://www.roche.com/media/releases/med-cor-2021-03-22b)
146. [Rodrigues and Ferreira (2017b)](https://pubmed.ncbi.nlm.nih.gov/29052699/)
147. [Rodrigues et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573977/)
148. [Rodriguez Santana et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9757103/)
149. [Rodríguez Santana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11962051/)
150. [Rodríguez-Santana et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-patient-poster-final-version-pdf.pdf)
151. [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)
152. [Roiboit and Stout (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12839483/)
153. [Roos (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3022767/)
154. [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)
155. [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)
156. [Sawant et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020898/)
157. [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)
158. [Sellers et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31466515/)
159. [Shaw et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/35073826/)
160. [Shaw et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9277690/)
161. [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)
162. [Skyhawk Therapeutics chief commercial officer announcement (2026)](https://www.skyhawktx.com/article/skyhawk-therapeutics-appoints-aaron-deves-as-chief-commercial-officer-to-lead-commercialization-of-sky-0515-for-huntingtons-disease)
163. [Skyhawk Therapeutics community letter (2026)](https://hdsa.org/wp-content/uploads/2026/01/Final-v2-%E2%80%93-Clean-SKY-0515_Community-Letter_Nine-Month-Phase-1C-Patient-Data_26JAN2026.pdf)
164. [Skyhawk Therapeutics EHDN 2024 presentation announcement (2024)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntingtons-disease-network-and-enroll-hd-2024-302244451.html)
165. [Skyhawk Therapeutics FALCON-HD expansion announcement (2026)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-expansion-of-its-global-pivotal-falcon-hd-clinical-trial-for-sky-0515-in-huntingtons-disease-to-the-united-states-canada-and-the-united-kingdom-302825053.html)
166. [Skyhawk Therapeutics FALCON-HD first patient dosed announcement (2025)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-first-patient-dosed-in-phase-23-falcon-hd-trial-of-sky-0515-for-huntingtons-disease-302483907.html)
167. [Skyhawk Therapeutics fifteen-month results announcement (2026)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-final-fifteen-month-results-from-phase-12-clinical-trial-of-sky-0515-in-huntingtons-disease-patients-302879406.html)
168. [Skyhawk Therapeutics first interim results announcement (2025)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-positive-first-interim-results-in-patients-from-its-phase-1-clinical-trial-of-sky-0515-as-a-treatment-for-huntingtons-disease-302559083.html)
169. [Skyhawk Therapeutics nine-month results announcement (2026)](https://www.prnewswire.com/apac/news-releases/skyhawk-therapeutics-announces-nine-month-interim-results-in-patients-from-its-phase-1-clinical-trial-of-sky-0515-as-a-treatment-for-huntingtons-disease-302670773.html)
170. [Skyhawk Therapeutics phase 1 topline results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/10/2911098/0/en/Skyhawk-Therapeutics-Announces-Positive-Topline-Results-from-Parts-A-and-B-of-its-Phase-1-Clinical-Trial-of-SKY-0515-as-a-Treatment-for-Huntington-s-Disease-Reaching-72-Huntingtin-.html)
171. [Skyhawk Therapeutics TGA eligibility announcement (2026)](https://www.prnewswire.com/apac/news-releases/skyhawk-announces-australias-therapeutic-goods-administration-has-determined-sky-0515-for-huntingtons-disease-meets-eligibility-criteria-for-registration-via-the-provisional-approval-pathway-302701184.html)
172. [Skyhawk Therapeutics treatment duration extension announcement (2024)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-receives-australian-regulatory-approval-to-extend-sky-0515-treatment-duration-in-phase-1-huntingtons-disease-patient-trial-302326386.html)
173. [Skyhawk Therapeutics twelve-month cUHDRS subcomponent announcement (2026)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-releases-twelve-month-cuhdrs-subcomponent-results-from-its-phase-12-clinical-trial-of-sky-0515-in-huntingtons-disease-302814409.html)
174. [Skyhawk Therapeutics twelve-month results announcement (2026)](https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-twelve-month-interim-results-from-phase-12-clinical-trial-of-sky-0515-in-huntingtons-disease-302786676.html)
175. [Smith et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522420/)
176. [Snowden (2017)](https://pubmed.ncbi.nlm.nih.gov/28961886/)
177. [Sokol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9436638/)
178. [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/)
179. [Solberg et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5870025/)
180. [Stoker et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34413240/)
181. [Sullivan et al. (2014)](https://www.valueinhealthjournal.com/article/S1098-3015%2813%2904235-6/fulltext)
182. [Tabrizi et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23664844/)
183. [Tabrizi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32796930/)
184. [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)
185. [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)
186. [Thorley et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6132452/)
187. [To et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373050/)
188. [To et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37350423/)
189. [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf)
190. [Trundell et al. (2019)](https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P1.8-043)
191. [uniQure (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)
192. [uniQure BLA plan announcement (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)
193. [uniQure BLA submission announcement (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)
194. [uniQure regulatory update (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2)
195. [van der Zwaan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35379551/)
196. [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)
197. [Vonsattel et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/2932539/)
198. [Walker (2007)](https://pubmed.ncbi.nlm.nih.gov/17240289/)
199. [Watkins et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30198875/)
200. [Wesson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108173/)
201. [Wexler et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769413/)
202. [Wheelock et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12654967/)
203. [Willock et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-caregiver-poster-final-version-pdf.pdf)
204. [Willock et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38108355/)
205. [Winder et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30103341/)
206. [Yohrling et al. (2019)](https://medically.gene.com/content/dam/pdmahub/restricted/neurology/hsg-2019/HSG-2019-poster-yohrling-prevalence-of-huntington-s-disease-in-the-US.pdf)
207. [Yohrling et al. (2020)](https://www.neurology.org/doi/10.1212/WNL.94.15_supplement.954)
208. [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)
209. [Youssov et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)
210. [Youssov et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41014964/)
211. [Yu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30594932/)

## Related pages
- [SKY-0515: Huntington's disease](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease.md)
- [SKY-0515 in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/terms-and-abbreviations.md)
- [SKY-0515: Huntington's disease](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/executive-summary.md)
- [SKY-0515 in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/product-information-and-disease-description.md)
- [SKY-0515 in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/clinical-evidence.md)
- [SKY-0515 in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/economics.md)
- [SKY-0515 in Huntington's disease: formulary monograph](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/monograph) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/monograph.md)
- [SKY-0515 in Huntington's disease: prevalence by geography](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/prevalence) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/prevalence.md)
- [SKY-0515 in Huntington's disease: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/cost-effectiveness-analyses.md)
- [SKY-0515 in Huntington's disease: interactive budget impact model](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/budget-impact-model) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/budget-impact-model.md)
- [SKY-0515 in Huntington's disease: cost-effectiveness model](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/cost-effectiveness-model) · [Markdown](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/cost-effectiveness-model.md)
